
Appendix

Reslizumab has just been assigned a permanent J code (J 2786). However, an average sales price (ASP) has yet to emerge from the marketplace. During the interim, a temporary J code is being used (unclassified biologic). It is expected that an ASP will emerge around Spring 2018, at which time we will provide an updated reimbursement range/number. It should be noted that there is a price differential for the reimbursement received for a temporary J code (typically based on the price of acquisition) versus that for a permanent J code.



Best Practices for Obtaining Reimbursements

Kristin Epland, MSN, FNP-C Midwest Immunology Clinic and Infusion Centel

Additional codes that may be helpful when submitting for reimbursement with the aforementioned therapies include

O CPT Description

- > Cinqair (reslizumab): J2786J2786-JW Cinqair (reslizumab) waste
- > Gamunex-C (IVIG or SCIG): J1561
- > Privigen (IVIG): 1459
- > IV infusion: 96365

- > A4222 Gammagard (IVIG): J1569
- > Nucala (mepolizumab): J2182
- > Xolair (omalizumab): J2357
- > Infusion supplies A4222